Z

    Zai Lab Ltd (ZLAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.46
    -0.62 (-2.38%)

    Market Cap: $2.93B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(19/35)
    Avg Surprise
    -0.63%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.56
    Range$-0.67 - $-0.49
    6 analysts
    EPS Revisions
    2
    0
    7d
    2
    2
    30d
    EPS Estimate Drift
    90d ago$-0.53+6.5%
    60d ago$-0.53+6.5%
    30d ago$-0.54+5.0%
    7d ago$-0.58-2.3%
    Current$-0.56
    Revenue Consensus
    $109M
    Range$105M - $112M
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.42
    Range$-0.98 - $0.18
    10 analysts
    Revenue Consensus
    $107M
    Range$95M - $129M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.42---
    Sep 26EST
    		-$-0.56---
    Jun 26
    		$-0.46$-0.66+30.30%Beat-24.3%
    Mar 26
    		$-0.46$-0.29-58.13%Miss-2.2%
    Dec 25
    		$-0.46$-0.44-4.55%Miss+42.5%
    Sep 25
    		$-0.33$-0.29-13.79%Miss+21.4%
    Jun 25
    		$-0.37$-0.37+0.00%Beat+54.9%
    Mar 25
    		$-0.45$-0.55+18.18%Beat+10.0%
    Dec 24
    		$-0.80$-0.63-26.32%Miss+18.4%
    Sep 24
    		$-0.42$-0.78+46.15%Beat+40.8%
    Jun 24
    		$-0.82$-0.73-12.33%Miss+34.4%
    Mar 24
    		$-0.50$-0.92+45.65%Beat+2.0%
    Dec 23
    		$-0.98$-0.87-12.64%Miss-50.8%
    Sep 23
    		$-0.71$-1.03+31.07%Beat+57.7%
    Jun 23
    		$-1.25$-0.81-54.32%Miss+13.2%
    Mar 23
    		$-0.51$-0.97+47.42%Beat+40.7%
    Dec 22
    		$-0.65$-1.11+41.44%Beat+70.0%
    Sep 22
    		$-1.68$-1.25-34.40%Miss-66.3%
    Jun 22
    		$-1.44$-1.07-34.58%Miss+18.2%
    Mar 22
    		$-0.86$-1.23+30.08%Beat+67.4%
    Dec 21
    		$-2.17$-1.33-63.16%Miss-445.0%
    Sep 21
    		$-1.01$-1.27+20.47%Beat-153.6%
    Jun 21
    		$-1.76$-1.39-26.62%Miss-162.7%
    Mar 21
    		$-2.64$-2.30-14.78%Miss-166.7%
    Dec 20
    		$-0.40N/A+59.78%Beat+41.4%
    Sep 20
    		$-0.40$-0.40+0.45%Beat+33.1%
    Jun 20
    		$-0.67$-0.99+32.32%Beat-55.8%
    Mar 20
    		$-0.99$-0.99+0.01%Beat-47.4%
    Dec 19
    		$-0.68$-0.60-13.33%Miss+0.0%
    Sep 19
    		$-0.60$-0.60+0.78%Beat-80.4%
    Jun 19
    		$-0.43$-0.67+35.82%Beat-65.4%
    Mar 19
    		$-0.67$-0.44-52.66%Miss-168.7%
    Dec 18
    		$-0.68$-0.45-51.11%Miss+82.8%
    Sep 18
    		$-0.33$-0.40+17.50%Beat-57.1%
    Jun 18
    		$-0.26$-0.38+31.58%Beat+65.1%
    Mar 18
    		$-0.25$-0.17-47.06%Miss+97.8%
    Dec 17
    		$-3.95$0.00N/ABeat-419.6%
    Sep 17
    		$-0.21$-0.23+8.70%Beat+98.4%
    Jun 17
    		$-0.74N/AN/ABeat-
    Mar 17
    		$-11.49N/AN/ABeat-
    Dec 16
    		$-0.76$0.00N/AMiss-
    Sep 16
    		$-13.32N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-14.89EV/EBITDA-2.35x
    Price/FCF-17.50xFCF Yield-5.71%
    Profitability
    Profit Margin-41.90%Operating Margin-72.00%
    ROE-26.90%ROIC-21.57%
    Financial Health
    Debt/Equity0.39xInterest Coverage-30.87x
    Current Ratio2.13xQuick Ratio1.92x
    Trading Statistics
    Beta0.78Avg Volume1.26M
    52-Week High$34.7252-Week Low$15.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.05
    SMA 20$24.71
    SMA 50$21.43
    SMA 200$19.74
    EMA 10$25.73
    EMA 20$24.64
    EMA 50$22.41
    EMA 200$22.02

    MACD

    Line: 1.52Signal: 1.64Hist: -0.12

    ADX

    ADX: 40.8+DI: 39.7-DI: 23.7

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down12.0
    PSAR$24.17

    Bollinger Bands

    Upper Band$29.80
    Lower Band$19.62
    %B Position4117%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    60.4

    Momentum Oscillators

    Stoch %K59.7
    Stoch %D72.3
    Williams %R-71.3
    ROC (10d)-0.7%
    Momentum-0.18
    CCI (20d)23.8
    MFI (14d)37.7

    Volatility Measures

    ATR (14d)$1.08(4.2%)
    StdDev (20d)2.54
    Hist Vol76.0%(High)

    Volume Flow

    VWAP$25.29
    OBV-17.3M
    AD Line-4.3M
    CMF (20d)0.303

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.7x
    VWMA (20d)$25.17

    Pivot Points

    R3$26.98
    R2$26.71
    R1$26.40
    Pivot Point$26.13
    S1$25.82
    S2$25.55
    S3$25.23

    Advanced Oscillators

    TSI38.47
    Ultimate Osc53.8
    KST322.07

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$106.31M$99.61M$127.60M$116.09M$109.98M$106.49M$109.07M$102.27M$100.50M$87.15M$65.83M$69.23M
    Cost of Revenue$48.16M$38.34M$62.33M$46.88M$43.22M$38.65M$42.09M$36.92M$35.23M$33.62M$25.24M$25.48M
    Gross Profit$58.15M$61.28M$65.27M$69.21M$66.76M$67.84M$66.98M$65.35M$65.27M$53.53M$40.59M$43.75M
    Operating Expenses$134.64M$130.56M$134.67M$118.03M$121.65M$124.15M$134.87M$133.20M$141.34M$123.84M$164.57M$127.32M
    R&D$61.77M$65.59M$61.63M$47.93M$50.61M$60.73M$52.25M$65.98M$61.63M$54.65M$81.95M$58.77M
    SG&A$72.87M$65.07M$73.04M$41.32M$42.68M$63.42M$82.62M$67.22M$79.71M$69.19M$82.63M$68.55M
    Operating Income$-76,489,000$-69,279,000$-69,406,000$-48,822,000$-54,895,000$-56,311,000$-67,891,000$-67,853,000$-76,064,000$-70,309,000$-123,981,000$-83,570,000
    Interest Income$5.88M$6.45M$7.25M$8.35M$8.84M$8.61M$9.09M$9.03M$9.33M$9.66M$10.30M$9.17M
    Interest Expense$1.59M$1.64M$1.36M$1.40M$1.26M$1.19M$904,000$745,000$492,000$113,000$20.38M$0
    Income Before Tax$-51,847,000$-49,576,000$-53,336,000$-35,963,000$-40,727,000$-48,438,000$-81,684,000$-41,671,000$-80,277,000$-53,471,000$-95,429,000$-69,152,000
    Income Tax Expense$-1,022,000$1.44M$-2,927,000$0$0$0$0$0$0$9.47M$-21,769,000$-9,172,000
    Net Income$-50,825,000$-51,016,000$-50,409,000$-35,963,000$-40,727,000$-48,438,000$-81,684,000$-41,671,000$-80,277,000$-53,471,000$-95,429,000$-69,152,000
    EBITDA$-46,087,000$-43,995,000$-48,059,000$-30,662,000$-35,730,000$-43,793,000$-75,433,000$-38,055,000$-76,844,000$-50,346,000$-119,089,000$-67,234,000
    EBIT$-50,260,000$-47,939,000$-51,975,000$-34,563,000$-39,465,000$-47,251,000$-80,780,000$-40,926,000$-79,785,000$-53,358,000$-121,548,000$-69,152,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ZLAB

    News

    How Investors Are Reacting To Zai Lab (ZLAB) Phase 3 VYVGART Hytrulo Autoimmune Myositis Data

    Zai Lab (ZLAB) and Argenx announced positive Phase 3 ALKIVIA results for VYVGART Hytrulo in autoimmune myositis, showing significant improvements and a consistent safety profile. This data strengthens Zai Lab's immunology portfolio, complementing its oncology focus. The article emphasizes that while these results are promising, the company's investment narrative still hinges on successful execution in China, timely approvals, and navigating pricing pressures.

    Simply Wall Street•8/22/26•
    Bullish

    How Investors Are Reacting To Zai Lab (ZLAB) Phase 3 VYVGART Hytrulo Autoimmune Myositis Data

    Zai Lab and Argenx announced positive Phase 3 ALKIVIA results for VYVGART Hytrulo in autoimmune myositis, showing significant improvements and a consistent safety profile. This data strengthens Zai Lab's immunology portfolio, complementing its oncology focus, though the investment narrative still heavily relies on successful product launches, label expansions, and favorable reimbursement decisions in China. Despite promising myositis data, investors need to consider China's pricing pressures and varying analyst expectations regarding Zai Lab's future profitability and revenue growth.

    Simply Wall Street•8/21/26•
    Bullish

    Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

    This article compares argenx SE (ARGX) and Zai Lab Limited (ZLAB) following positive Phase 3 study results for VYVGART Hytrulo in autoimmune myositis. While both companies benefit from a licensing agreement for the drug in Greater China, argenx shows significantly greater financial scale and profitability, driven by strong global sales. Zai Lab, despite sequential revenue growth and an expanding portfolio, continues to face operating losses.

    Yahoo Finance UK•8/20/26•
    Somewhat-Bearish

    Former Zai Lab (NASDAQ: ZLAB) executive lines up multi-million ADS sale

    A former officer of Zai Lab Ltd (ZLAB), Joshua L. Smiley, has filed a Form 144 notice for the potential sale of 98,653 American Depositary Shares (ADSs), valued at approximately $2.58 million. These shares originate from a stock option exercise and are expected to be sold on August 20, 2026, through Fidelity Brokerage Services LLC on NASDAQ. The filing provides details on the transaction, including the number of shares, aggregate market value, and the approximate sale date.

    Stock Titan•8/20/26•
    Neutral

    Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

    argenx SE (ARGX) and Zai Lab Limited (ZLAB) both reported positive Phase 3 study results for VYVGART Hytrulo in autoimmune myositis, with argenx shares reaching an all-time high. While Zai Lab has a licensing agreement for Greater China, argenx demonstrates significantly larger financial scale and profitability, driven by global VYVGART sales, whereas Zai Lab faces operating losses despite sequential revenue growth. Investors are watching for FDA decisions on dermatomyositis trials and Zai Lab's commercial execution to curb losses.

    Yahoo Finance•8/20/26•
    Somewhat-Bearish

    Frequently Asked Questions About ZLAB

    Does ZLAB pay dividends?
    Zai Lab Ltd (ZLAB) does not currently pay a regular dividend.
    What is ZLAB's market cap?
    Zai Lab Ltd (ZLAB) has a market capitalization of $2.93B with a current stock price of $25.46.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In